![]() Stifel 2023 Cross Sector Insight Conference in Boston, MA, June 6-7 and.Benchmark’s Healthcare House Call VIRTUAL One-on-One Conference, May 23.RBC Capital Markets 2023 Global Healthcare Conference in New York, NY, May 16-17.Members of TRHC’s executive team are currently expected to be present at the following conferences: To provide transparency into our financial results, we are providing the following operational metrics.Ī reconciliation of the projected adjusted EBITDA from continuing operations has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.” $1.1 million (1.6% of revenue) in the first quarter of 2022.Ī reconciliation of certain financial measures with the most directly comparable financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”) has been provided in this press release in the accompanying tables. Adjusted EBITDA – Adjusted EBITDA from continuing operations of $4.7 million (5.4% of revenue) increased 337% vs.As previously announced on March 2, 2023, TRHC completed the sales of SinfoníaRx and DoseMe during the first quarter of 2023. Both periods include the SinfoníaRx and DoseMe businesses. GAAP net loss from discontinued operations (net of tax) of $8.8 million compares to a net loss of $7.8 million in the first quarter of 2022. the prior year was primarily driven by the higher gross profit noted above and a reduction in operating expenses. GAAP Net Loss – GAAP net loss from continuing operations of $7.1 million compared to a net loss of $20.4 million in the first quarter of 2022.Both medication and technology-enabled solutions gross margin increased vs. Adjusted gross profit of $21.2 million (24.1% of revenue) increased 33% as compared to $15.9 million (23.8% of revenue) a year ago. ![]() Gross Profit – Gross profit (exclusive of depreciation and amortization) of $20.8 million (23.5% of revenue) increased 44% as compared to $14.4 million (21.4% of revenue) in the first quarter of 2022.Technology-enabled solutions revenue growth was driven by our pharmacy benefits management (“PBM”) and risk adjustment services. Technology-enabled solutions revenue of $19.5 million increased 21% compared to $16.1 million in the first quarter of 2022 and increased 7% as compared to the fourth quarter of 2022. Medication revenue of $68.8 million increased 35% due to continued strong PACE census growth at existing centers and higher revenue per PACE participant. Revenue – Revenue of $88.3 million increased 32% compared to $67.1 million in the first quarter of 2022 and increased 7% as compared to the fourth quarter of 2022.Adjusted net loss from continuing operationsĪdjusted EBITDA from continuing operationsĪll comparisons, unless otherwise noted, are to the three months ended March 31, 2022, and reflect continuing operations. ![]()
0 Comments
Leave a Reply. |